Clinical Trial Update: Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial results for subcutaneous AC2307 in obese or overweight adults report safety, tolerability and impact on body weight.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• AC2307

Snippet

Sponsor: AstraZeneca | Conditions: Obesity, Overweight | Phase 2 | Status: COMPLETED